A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved. We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients. METHODS: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 weeks. The primary end point was the change in FVC or death at week 52. Secondary end points were the 6-minute walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis. RESULTS: In the pirfenidone group, as compared with the placebo group, there was a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P<0.001). Pirfenidone reduced the decline in the 6-minute walk distance (P=0.04) and improved progression-free survival (P<0.001). There was no significant between-group difference in dyspnea scores (P=0.16) or in rates of death from any cause (P=0.10) or from idiopathic pulmonary fibrosis (P=0.23). However, in a prespecified pooled analysis incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P=0.01) and from idiopathic pulmonary fibrosis (P=0.006). Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation. CONCLUSIONS: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [191]
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“In three trials with doses that reached 2403 mg/day, pirfenidone effectively reduced FVC decline although had variable reductions in overall mortality and IPF-related mortality [12,13].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [45]
In the citing paper
“FVC is the gold-standard metric for assessing the lung function of patients with IPF and response to therapeutic intervention33–35.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [35]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationDouble-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citation
Cited by
Items 1,001–1,100 of 3,965
Oxygen therapy in COPD and interstitial lung disease: navigating the knowns and unknowns
Khor, Y. H., Renzoni, E. A., Visca, D., McDonald, C. F., & Goh, N. S. L. (2019) · ERJ Open Research · doi:10.1183/23120541.00118-2019 · Cited by 43
Chung, M. P., Park, M. S., Oh, I., Lee, H. B., Kim, Y. W., Park, J. S., Uh, S. T., Kim, Y. S., Jegal, Y., & Song, J. W. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01328-8 · Cited by 44
Corral, M., DeYoung, K., & Kong, A. M. (2020) · BMC Pulmonary Medicine · doi:10.1186/s12890-020-01224-5 · Cited by 39
Ruigrok, M. J. R., Frijlink, H. W., Melgert, B. N., Olinga, P., & Hinrichs, W. L. J. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.01.003 · Cited by 45
Shimbori, C., Bellaye, P., Kolb, P., & Kolb, M. R. J. (2017) · Milestones in drug therapy · doi:10.1007/978-3-0348-0977-1_3 · Cited by 38
Mattoo, H., & Pillai, S. S. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03874-y · Cited by 40
Guardela, B. J., Sun, J., Zhang, T., Xu, B., Balnis, J., Huang, Y., Ma, S., Molyneaux, P. L., Maher, T. M., Noth, I., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103439 · Cited by 39
“The use of 50-gene risk profiles could also support the rationale to investigate the use of IPF-targeted antifibrotic medications [27,28] to prevent shortand long-term sequela of COVID-19.”
Systemic Sclerosis: From Pathophysiology to Novel Therapeutic Approaches
Benfaremo, D., Svegliati, S., Paolini, C., Agarbati, S., & Moroncini, G. (2022) · Biomedicines · doi:10.3390/biomedicines10010163 · Cited by 46
Wang, J., Wang, X., Qi, X., Sun, Z.-J., Zhang, T., Cui, Y., & Shu, Q. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.871861 · Cited by 45
Update on diagnosis and treatment of idiopathic pulmonary fibrosis
Martínez, J. A. B., Baldi, B. G., da Costa, C. H., Jezler, S. F. D. O., Lima, M. S., & Rufino, R. (2015) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132015000000152 · Cited by 43
Clinical characteristics of idiopathic pulmonary fibrosis patients according to their smoking status
Kishaba, T., Nagano, H., Nei, Y., & Yamashiro, S. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2016.03.89 · Cited by 37
Müller, T., Fay, S., Vieira, R. P., Karmouty‐Quintana, H., Cicko, S., Ayata, C. K., Zissel, G., Goldmann, T., Lungarella, G., Ferrari, D., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16414 · Cited by 45
Kast, R. E., Skuli, N., Karpel‐Massler, G., Fròsina, G., Ryken, T. C., & Halatsch, M. (2017) · Oncotarget · doi:10.18632/oncotarget.18337 · Cited by 41
Pharmacological management of IPF
Borie, R., Justet, A., Beltramo, G., Manali, E. D., Pradère, P., Spagnolo, P., & Crestani, B. (2016) · Respirology · doi:10.1111/resp.12778 · Cited by 42
β-catenin activates TGF-β-induced epithelial–mesenchymal transition in adenomyosis
Yoo, J., Ku, B. J., Kim, T. H., Ahn, J. I., Ahn, J. Y., Yang, W. S., Lim, J. M., Taketo, M. M., Shin, J., & Jeong, J. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00514-6 · Cited by 48
Animal models of acute exacerbation of pulmonary fibrosis
Xu, Y., Zhang, M., Gu, H., Liu, M., Zhao, Y., Shi, Y., Wu, S., Jiang, C., Ye, X., Zhu, H., et al. (2023) · Respiratory Research · doi:10.1186/s12931-023-02595-z · Cited by 43
Strookappe, B., Elfferich, M., Swigris, J. J., Verschoof, A. C., Veschakelen, J., Knevel, T., & Drent, M. (2015) · Sarcoidosis vasculitis and diffuse lung diseases · Cited by 36
Self-citationNew perspectives on management of idiopathic pulmonary fibrosis
Puglisi, S., Torrisi, S. E., Vindigni, V., Giuliano, R., Palmucci, S., Mulè, M., & Vancheri, C. (2016) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315624276 · Cited by 38
Hospital cost and length of stay in idiopathic pulmonary fibrosis
Mooney, J. J., Raimundo, K., Chang, E. Y., & Broder, M. S. (2017) · Journal of Medical Economics · doi:10.1080/13696998.2017.1282864 · Cited by 38
Inhibition of the KCa3.1 Channel Alleviates Established Pulmonary Fibrosis in a Large Animal Model
Organ, L. A., Bacci, B., Koumoundouros, E., Kimpton, W. G., Samuel, C. S., Nowell, C. J., Bradding, P., Roach, K. M., Westall, G. P., Jaffar, J., et al. (2017) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2016-0092oc · Cited by 39
The fibrogenic actions of lung fibroblast-derived urokinase: a potential drug target in IPF
Schuliga, M. J., Jaffar, J., Harris, T., Knight, D. A., Westall, G. P., & Stewart, A. G. (2017) · Scientific Reports · doi:10.1038/srep41770 · Cited by 36
Xaubet, A., Ancochea, J., & Molina‐Molina, M. (2017) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2016.11.035 · Cited by 45
Burden, resilience and coping in caregivers of patients with interstitial lung disease
Shah, R., Collard, H. R., & Morisset, J. (2018) · Heart & Lung · doi:10.1016/j.hrtlng.2018.03.004 · Cited by 40
Multidisciplinary Evaluation in Patients with Lung Disease Associated with Connective Tissue Disease
Wells, A., Devaraj, A., Renzoni, E. A., & Denton, C. P. (2019) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-1684020 · Cited by 36
Zulfikar, S., Mulholland, S., Adamali, H. I., & Barratt, S. L. (2020) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s228362 · Cited by 41
Chu, K.-A., Yeh, C., Kuo, F.-H., Lin, W.-R., Hsu, C.-W., Chen, T.-H., & Fu, Y.-S. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-02012-y · Cited by 38
Türkkan, G., Willems, Y. C. P., Hendriks, L. E. L., Mostard, R. L. M., Conemans, L. H., Gietema, H. A., Mitea, C., Peeters, S., & Ruysscher, D. D. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.11.020 · Cited by 38
Pirfenidone Clinical Study Group in Japan, Ikeda, K., Chiba, H., Nishikiori, H., Azuma, A., Kondoh, Y., Ogura, T., Taguchi, Y., Ebina, M., Sakaguchi, H., et al. (2020) · Respiratory Research · doi:10.1186/s12931-020-01582-y · Cited by 36
Wright, W. A., Crowley, L., Parekh, D., Crawshaw, A., Dosanjh, D. P. S., Nightingale, P., & THICKETT, D. R. (2021) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2020-000782 · Cited by 47
Si-Mohamed, S. A., Nasser, M., Colevray, M., Nempont, O., Lartaud, P.-J., Vlachomitrou, A. S., Broussaud, T., Ahmad, K., Traclet, J., Cottin, V., et al. (2022) · European Radiology · doi:10.1007/s00330-021-08482-9 · Cited by 42
Which Patients With ARDS Benefit From Lung Biopsy?
Palakshappa, J. A., & Meyer, N. J. (2015) · CHEST Journal · doi:10.1378/chest.15-0076 · Cited by 36
Lindell, K. O., Nouraie, M. S., Klesen, M. J., Klein, S. J., Gibson, K. F., Kass, D. J., & Rosenzweig, M. Q. (2018) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2017-000272 · Cited by 38
Fibroblast-derived extracellular vesicles contain SFRP1 and mediate pulmonary fibrosis
Burgy, O., Mayr, C. H., Schenesse, D., Fousekis-Papakonstantinou, E., Ballester, B., Sengupta, A., She, Y., Hu, Q., Melo-Narváez, M. C., Jain, E., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.168889 · Cited by 43
Progressive lung fibrosis: reprogramming a genetically vulnerable bronchoalveolar epithelium
Bridges, J. P., Vladar, E. K., Kurche, J. S., Krivoi, A., Stancil, I. T., Dobrinskikh, E., Hu, Y., Sasse, S. K., Lee, J. S., Blumhagen, R. Z., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci183836 · Cited by 46
Symptom‐based management of the idiopathic interstitial pneumonia
Garibaldi, B. T., & Danoff, S. K. (2015) · Respirology · doi:10.1111/resp.12649 · Cited by 40
Zanotti, S., Bragato, C., Zucchella, A., Maggi, L., Mantegazza, R., Morandi, L. O., & Mora, M. (2015) · Life Sciences · doi:10.1016/j.lfs.2015.12.015 · Cited by 36
Sato, S., Hanibuchi, M., Takahashi, M., et al. (2016) · Internal Medicine · doi:10.2169/internalmedicine.55.5047 · Cited by 35
Idiopathic Pulmonary Fibrosis: Diagnosis and Clinical Manifestations
Nakamura, Y., & Suda, T. (2015) · Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine · doi:10.4137/ccrpm.s39897 · Cited by 49
Xaubet, A., Ancochea, J., & Molina‐Molina, M. (2016) · Medicina Clínica · doi:10.1016/j.medcli.2016.11.004 · Cited by 41
A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK
Rinciog, C., Watkins, M., Chang, S., Maher, T. M., LeReun, C., Esser, D., & Diamantopoulos, A. (2016) · PharmacoEconomics · doi:10.1007/s40273-016-0480-2 · Cited by 39
Clinical trial research in focus: why do so many clinical trials fail in IPF?
Spagnolo, P., & Maher, T. M. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30122-4 · Cited by 39
S2k-Leitlinie Idiopathische Lungenfibrose – Update zur medikamentösen Therapie 2017
Behr, J., Günther, A., Bonella, F., Geissler, K. H., Koschel, D., Kreuter, M., Prasse, A., Schönfeld, N., Sitter, H., Müller–Quernheim, J., et al. (2017) · Pneumologie · doi:10.1055/s-0043-106160 · Cited by 37
Beneficial effects of bile acid receptor agonists in pulmonary disease models
Comeglio, P., Morelli, A., Adorini, L., Maggi, M., & Vignozzi, L. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1385760 · Cited by 43
The relationship between complement C3 expression and the MUC5B genotype in pulmonary fibrosis
Okamoto, T., Mathai, S. K., Hennessy, C. E., Hancock, L. A., Walts, A. D., Stefanski, A. L., Brown, K. K., Lynch, D. A., Cosgrove, G. P., Groshong, S. D., et al. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00395.2017 · Cited by 37
CCR10+ epithelial cells from idiopathic pulmonary fibrosis lungs drive remodeling
Habiel, D. M., Espindola, M. S., Jones, I. C., Coelho, A. L., Stripp, B., & Hogaboam, C. M. (2018) · JCI Insight · doi:10.1172/jci.insight.122211 · Cited by 35
Gu, T.-T., Chen, T., Yang, Y.-Z., Zhao, X., Sun, Y., Li, T., Zhang, D., & Kong, L. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.10.008 · Cited by 40
Soluble Thy-1 reverses lung fibrosis via its integrin-binding motif
Tan, C., Jiang, M., Wong, S. S., Espinoza, C. R., Kim, C., Li, X., Connors, E. P., & Hagood, J. S. (2019) · JCI Insight · doi:10.1172/jci.insight.131152 · Cited by 36
“Current FDA-approved medication has only decelerated the ongoing tissue remodeling, rather than halting or reversing it (1, 2).”
BackgroundTaha, N., D’Amato, D., Hosein, K., Ranalli, T., Sergiacomi, G., Zompatori, M., & Mura, M. (2020) · Respiratory Research · doi:10.1186/s12931-020-01371-7 · Cited by 35
Spencer, L. G., Loughenbury, M., Chaudhuri, N., Spiteri, M. A., & Parfrey, H. (2020) · ERJ Open Research · doi:10.1183/23120541.00187-2020 · Cited by 40
Ion therapy of pulmonary fibrosis by inhalation of ionic solution derived from silicate bioceramics
Chen, T., Zhang, Z., Weng, D., Lu, L., Wang, X., Xing, M., Qiu, H., Zhao, M., Shen, L., Zhou, Y., et al. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.02.013 · Cited by 49
Roberts, M. J., May, L. T., Keen, A. C., Liu, B., Lam, T., Charlton, S. J., Rosethorne, E. M., & Halls, M. L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.669227 · Cited by 37
“Again ∼15% of participants discontinued use of pirfenidone due to severe adverse effects (Noble et al., 2011; King et al., 2014).”
BackgroundShumar, J. N., Chandel, A., & King, C. S. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112285 · Cited by 38
Sangani, R. G., Ghio, A. J., Culp, S., Patel, Z., & Sharma, S. (2021) · International Journal of COPD · doi:10.2147/copd.s307192 · Cited by 37
Wijsenbeek, M. S., Grutters, J. C., & Wuyts, W. A. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0225-1 · Cited by 34
“The proportion of patients in this study who had an FVC decline C10% or died by 12 months was comparable with that reported in ASCEND [11].”
BackgroundMethodResultInfluentialNo relevant pharmacokinetic drug–drug interaction between nintedanib and pirfenidone
Richeldi, L., Fletcher, S., Adamali, H., Chaudhuri, N., Wiebe, S., Wind, S., Hohl, K., Baker, A., Schlenker-Herceg, R., Stowasser, S., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01060-2018 · Cited by 34
Comparison of Pirfenidone and Nintedanib
Kim, J. S., Murray, S., Yow, E., Anstrom, K. J., Kim, H. J., Flaherty, K. R., Martinez, F. J., & Noth, I. (2024) · CHEST · doi:10.1016/j.chest.2023.11.035 · Cited by 34
Role of dual-specificity protein phosphatase DUSP10/MKP-5 in pulmonary fibrosis
Xylourgidis, N., Min, K., Ahangari, F., Yu, G., Herazo‐Maya, J. D., Karampitsakos, Τ., Aidinis, V., Binzenhöfer, L., Bouros, D. E., Bennett, A. M., et al. (2019) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00264.2018 · Cited by 40
Organ, L. A., Bacci, B., Koumoundouros, E., Barcham, G., Milne, M., Kimpton, W. G., Samuel, C. S., & Snibson, K. J. (2015) · BMC Pulmonary Medicine · doi:10.1186/s12890-015-0071-6 · Cited by 39
“Whilst there are now two therapies available to slow the progression of the disease [2, 3], these therapies are unlikely to be effective in the entire spectrum of IPF patients and still do not address the fibrosis that results from aberrant wound healing and is a key contributor to organ failure.”
BackgroundTHICKETT, D. R., Kendall, C., Spencer, L. G., Screaton, N., Wallace, W. A., Pinnock, H., Bott, J., Pigram, L., Watson, S., & Millar, A. (2014) · Thorax · doi:10.1136/thoraxjnl-2014-206284 · Cited by 41
Sharp, C., McCabe, M., Hussain, M. J., Dodd, J. W., Lamb, H., Adamali, H. I., Millar, A., & Smith, D. (2016) · QJM · doi:10.1093/qjmed/hcw105 · Cited by 34
Wapenaar, M., Patel, A. S., Birring, S. S., van Domburg, R. T., Bakker, E. W. P., Vindigni, V., Sköld, C. M., Cottin, V., Vancheri, C., & Wijsenbeek, M. S. (2016) · Chronic Respiratory Disease · doi:10.1177/1479972316674425 · Cited by 40
Horimasu, Y., Ishikawa, N., Taniwaki, M., Yamaguchi, K., Hamai, K., Iwamoto, H., Ohshimo, S., Hamada, H., Hattori, N., Okada, M., et al. (2017) · BMC Medical Genetics · doi:10.1186/s12881-017-0449-9 · Cited by 38
Roberts, M. J., Broome, R., Kent, T. C., Charlton, S. J., & Rosethorne, E. M. (2018) · Respiratory Research · doi:10.1186/s12931-018-0759-2 · Cited by 38
Diverse functions of clusterin promote and protect against the development of pulmonary fibrosis
Peix, L., Evans, I., Pearce, D. R., Simpson, J. K., Maher, T. M., & McAnulty, R. J. (2018) · Scientific Reports · doi:10.1038/s41598-018-20316-1 · Cited by 32
Nathan, S. D., Costabel, U., Glaspole, I., Glassberg, M. K., LANCASTER, L. H., Lederer, D. J., Pereira, C. A. C., Trzaskoma, B. L., Morgenthien, E. A., Limb, S. L., et al. (2018) · CHEST Journal · doi:10.1016/j.chest.2018.11.008 · Cited by 39
Self-citationTargeting interleukin-13 in idiopathic pulmonary fibrosis: from promising path to dead end
Wijsenbeek, M. S., Kool, M., & Cottin, V. (2018) · European Respiratory Journal · doi:10.1183/13993003.02111-2018 · Cited by 36
Alberti, M. L., Ruiz, J. M., Fernández, M. E., Fassola, L., Caro, F. M., Buendía-Roldán, I., & Paulín, F. (2019) · Pulmonology · doi:10.1016/j.pulmoe.2019.08.007 · Cited by 37
CPAP Adherence, Mortality, and Progression-Free Survival in Interstitial Lung Disease and OSA
Adegunsoye, A., Neborak, J. M., Zhu, D., CANTRILL, B. N., Garcia, N. M., Oldham, J. M., Noth, I., Vij, R., Kuźniar, T. J., Bellam, S. K., et al. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.04.067 · Cited by 40
Yamamoto, Y., Yano, Y., Kuge, T., Okabe, F., Ishijima, M., Uenami, T., Kanazu, M., Akazawa, Y., Yamaguchi, T., & Mori, M. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13675 · Cited by 42
Song, M. J., Moon, S. W., Choi, J. S., Lee, S. H., Lee, S. H., Chung, K. S., Jung, J. Y., Kang, Y. A., Park, M. S., Kim, Y. S., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-77837-x · Cited by 35
Hermansky-Pudlak Syndrome and Lung Disease: Pathogenesis and Therapeutics
Velázquez-Díaz, P., Nakajima, E., Sorkhdini, P., Hernandez-Gutierrez, A., Eberle, A. T., Yang, D., & Zhou, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.644671 · Cited by 40
Nathan, S. D., Mehta, J., Stauffer, J. L., Morgenthien, E. A., Yang, M., Limb, S. L., & Bhorade, S. M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071427 · Cited by 35
Self-citationInterstitial Lung Disease in 2020
Guler, S. A., & Corte, T. J. (2021) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2021.03.001 · Cited by 43
Huang, K. Y., & Petretto, E. G. (2021) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00594.2020 · Cited by 43
Althobiani, M. A., Evans, R., Alqahtani, J. S., Aldhahir, A. M., Russell, A., Hurst, J. R., & Porter, J. C. (2021) · ERJ Open Research · doi:10.1183/23120541.00441-2021 · Cited by 37
Chandel, A., Pastré, J., Valéry, S., King, C. S., & Nathan, S. D. (2022) · Thorax · doi:10.1136/thoraxjnl-2021-218440 · Cited by 39
Self-citationDelivery of sorafenib by myofibroblast-targeted nanoparticles for the treatment of renal fibrosis
Cheng, H., Huang, H., Lee, T., Liao, Y., Sheng, Y.-H., Jin, P.-R., Huang, K., Chen, L.-H., Chen, Y., Lin, T., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.04.004 · Cited by 37
Salciccioli, J. D., Marshall, D. C., Goodall, R. J., Crowley, C., Shalhoub, J., PATEL, P., & Molyneaux, P. L. (2022) · ERJ Open Research · doi:10.1183/23120541.00058-2022 · Cited by 36
Lung Organoids—The Ultimate Tool to Dissect Pulmonary Diseases?
Bosáková, V., Zuani, M. D., Sládková, L., Garlíková, Z., Jose, S. S., Zelante, T., Kohoutková, M. H., & Frič, J. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.899368 · Cited by 39
“As a result of murine studies, two IPF drugs have been developed, pirfenidone (King et al., 2014) and nintedanib (Richeldi et al.”
BackgroundHER2 drives lung fibrosis by activating a metastatic cancer signature in invasive lung fibroblasts
Liu, X., Geng, Y., Liang, J., Coelho, A. L., Yao, C., Deng, N., Wang, Y., Dai, K., Huang, G., Xie, T., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20220126 · Cited by 36
“IPF is a chronic, progressive, fibrotic interstitial lung disease of unknown cause and is the most common and lethal idiopathic interstitial pneumonia (King et al., 2014; Noble et al., 2012).”
InfluentialSelf-citationAstaxanthin: A promising therapeutic agent for organ fibrosis
Li, K., Wang, W., & Xiao, W. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106657 · Cited by 40
Cathepsin K Contributes to Cavitation and Collagen Turnover in Pulmonary Tuberculosis
Kübler, A., Larsson, C., Luna, B. M., Andrade, B. B., Amaral, E. P., Urbanowski, M. E., Orandle, M. S., Bock, K. W., Ammerman, N. C., Cheung, L. S., et al. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv458 · Cited by 35
Idiopathic and immune‐related pulmonary fibrosis: diagnostic and therapeutic challenges
McLean‐Tooke, A. P., Moore, I., & Lake, F. (2019) · Clinical & Translational Immunology · doi:10.1002/cti2.1086 · Cited by 37
Fainberg, H. P., Moodley, Y. P., Triguero, I., Corte, T. J., Sand, J. M. B., Leeming, D. J., Karsdal, M. A., Wells, A. U., Renzoni, E. A., Mackintosh, J. A., et al. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(24)00147-4 · Cited by 44
Incorporating genetics into the identification and treatment of Idiopathic Pulmonary Fibrosis
Mathai, S. K., Yang, I. V., Schwarz, M. I., & Schwartz, D. A. (2015) · BMC Medicine · doi:10.1186/s12916-015-0434-0 · Cited by 37
Molecular Endotyping of Pulmonary Fibrosis
Goodwin, A. T., & Jenkins, G. R. (2015) · CHEST Journal · doi:10.1378/chest.15-1511 · Cited by 38
Treatments for idiopathic pulmonary fibrosis.
King, T. E., Noble, P. W., & Bradford, W. Z. (2014) · PubMed · doi:10.1056/nejmc1407776 · Cited by 20
Treatment of idiopathic pulmonary fibrosis: a position paper from a Nordic expert group
Sköld, C. M., Bendstrup, E. M., Myllärniemi, M., Guðmundsson, G., Sjåheim, T., Hilberg, O., Altraja, A., Kaarteenaho, R. L., & Ferrara, G. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12571 · Cited by 38
Idiopathic Pulmonary Fibrosis in Switzerland: Diagnosis and Treatment
Funke-Chambour, M., Azzola, A., Adler, D., Barazzone‐Argiroffo, C., Benden, C., Boehler, A., Bridevaux, P., Brutsche, M. H., Clarenbach, C. F., Hostettler, K., et al. (2017) · Respiration · doi:10.1159/000464332 · Cited by 36
Ikeda, K., Shiratori, M., Chiba, H., Nishikiori, H., Yokoo, K., Saito, A., Hasegawa, Y., Kuronuma, K., Otsuka, M., Yamada, G., et al. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.08.021 · Cited by 38
Modeling Idiopathic Pulmonary Fibrosis in Humanized Severe Combined Immunodeficient Mice
Habiel, D. M., Espíndola, M. S., Coelho, A. L., & Hogaboam, C. M. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.12.020 · Cited by 36
Diagnosis of asbestos-related lung diseases
Harris, E. J. A., Musk, A. W., de Klerk, N. H., Reid, A., Franklin, P., & Brims, F. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1568875 · Cited by 40
Quantitative CT‐derived vessel metrics in idiopathic pulmonary fibrosis: A structure–function study
Jacob, J., Pienn, M., Payer, C., Urschler, M., Kokosi, M. A., Devaraj, A., Wells, A. U., & Olschewski, H. (2019) · Respirology · doi:10.1111/resp.13485 · Cited by 33
Longitudinal prediction of outcome in idiopathic pulmonary fibrosis using automated CT analysis
Jacob, J., Bartholmai, B. J., van Moorsel, C. H. M., Rajagopalan, S., Devaraj, A., van Es, H. W., Moua, T., van Beek, F. T., Clay, R., Veltkamp, M., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.02341-2018 · Cited by 35
Torrisi, S. E., Kahn, N. C., Wälscher, J., Sarmand, N., Polke, M., Kehler, L., Eichinger, M., Heußel, C. P., Palmucci, S., Sambataro, F. M., et al. (2019) · BMC Pulmonary Medicine · doi:10.1186/s12890-019-0937-0 · Cited by 38
An Open-label Study With Pirfenidone on Chronic Hypersensitivity Pneumonitis
Mateos‐Toledo, H., Mejía, M. E., Rodríguez-Barreto, Ó., Mejía-Hurtado, J. G., Rojas‐Serrano, J., Estrada, A., Castillo-Pedroza, J., Castillo-Castillo, K., Gaxiola, M., Buendía-Roldán, I., et al. (2019) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2019.08.019 · Cited by 33
NADPH Oxidase Inhibition in Fibrotic Pathologies
Bernard, K. F., & Thannickal, V. J. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8032 · Cited by 34
Fibrotic Hypersensitivity Pneumonitis: Diagnosis and Management
Varone, F., Iovene, B., Sgalla, G., et al. (2020) · Lung · doi:10.1007/s00408-020-00360-3 · Cited by 33
Moor, C. C., Mostard, R. L. M., Grutters, J. C., Bresser, P., Aerts, J. G. J. V., Dirksen, C. D., Kimman, M., & Wijsenbeek, M. S. (2020) · Respiratory Research · doi:10.1186/s12931-020-01458-1 · Cited by 33
Nathan, S. D., Wanger, J. S., Zibrak, J. D., Wencel, M. L., Burg, C., & Stauffer, J. L. (2020) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2020.1816831 · Cited by 38
Self-citation
Metadata
- Authors
- King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W.
- Affiliations
- Cedars-Sinai Medical Center (US)
- The Alfred Hospital (AU)
- University of Miami (US)
- Prince Charles Hospital (AU)
- Vanderbilt University Medical Center (US)
- Columbia University Irving Medical Center (US)
- Inova Fairfax Hospital (US)
- Universidade Federal de São Paulo (BR)
- Medical University of South Carolina (US)
- Overlook Medical Center (US)
- National Jewish Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2083-2092
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168666423
- Cited by
- 3,975
- References
- 27
- Citations by year
- 2026: 272 · 2025: 303 · 2024: 371 · 2023: 315 · 2022: 339 · 2021: 412 · 2020: 343 · 2019: 310 · 2018: 335 · 2017: 319 · 2016: 288 · 2015: 279 · 2014: 76
- FWCI
- 256.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, disease progression, mortality, progression-free survival, 6-minute walk distance, dyspnea, gastrointestinal adverse effects, cutaneous adverse events, exercise tolerance, lung function decline, safety and tolerability
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antifibrinolytic Agents, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.